Search Results

You are looking at 11 - 20 of 654 items for :

  • "immunotherapy" x
  • Refine by Access: All x
Clear All
Full access

Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy

David D. Chism

OS of 6 to 9 months. 12 – 14 Both the unmet need for second-line therapies for bladder cancer and a resurgence of immunotherapy in other solid tumors coincided to provide the backdrop for the immunotherapy launch into bladder cancer. Ipilimumab, a

Full access

New Agents for Colorectal Cancer

Mary F. Mulcahy and Al B. Benson III

: 30 – 36 . 34 Harris JE Ryan L Hoover HC Jr . Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283 . J Clin Oncol 2000 ; 18 : 148

Full access

Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer

Brandon A. Dyer, Dmitriy Zamarin, Ramez N. Eskandar, and Jyoti M. Mayadev

Clinical Rationale to Explore Immunotherapy in Cervical Cancer Cervical cancer (CC) affects an estimated 12,900 women and accounts for 4,100 deaths annually in the United States, and is the most common gynecologic cancer worldwide. 1 The

Full access

Biomarker Testing for Immunotherapy

Jarushka Naidoo

Kimmel Comprehensive Cancer Center at Johns Hopkins, discussed the busy and growing area of biomarker testing for immunotherapy. Biomarkers are defined as “cellular, biochemical or molecular alterations that are measurable in biological media, such as

Full access

Principles of Immunotherapy

Anthony J. Olszanski

Immunotherapy has grabbed our attention [in oncology], and it is not the end of the story,” declared Anthony J. Olszanski, RPh, MD, Associate Professor, Director of the Phase I Developmental Therapeutics Program, and Director of the Medical

Full access

Immunotherapies for Lung Cancer

Matthew A. Gubens

Matthew A. Gubens, MD, MS, Assistant Clinical Professor of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discussed the past, present, and future of immunotherapies for non–small cell lung cancer (NSCLC) at the NCCN 22nd Annual

Full access

Controversies in the Surgical Management of Renal Cancer

Michael P. Porter and Paul H. Lange

Urol 2003 ; 169 : 2076 – 2083 . 37 Pantuck AJ Zisman A Dorey F . Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy . Cancer 2003 ; 97 : 2995 – 3002 . 38 Vasselli JR Yang

Full access

Update on Immunotherapy for Melanoma

Antoni Ribas

The author was supported in part by K23 CA93376 and the Melanoma Research Foundation during the preparation of this manuscript. References 1. Blattman JN Greenberg PD . Cancer immunotherapy: a treatment for the masses

Full access

Perioperative Systemic Therapy for Resectable Non–Small Cell Lung Cancer

Bharathi Muthusamy, Pradnya D. Patil, and Nathan A. Pennell

systemic therapy (neoadjuvant or adjuvant) for almost a decade. 6 Meanwhile, the widespread use of immunotherapy and targeted therapies has transformed the treatment of metastatic or unresectable NSCLC. These successes have further motivated research into

Full access

On the Verge: Immunotherapy for Colorectal Carcinoma

David Y. Oh, Alan P. Venook, and Lawrence Fong

for each patient, suggesting that patient-specific mutations may determine whether immunogenic responses are produced. Neoantigens also appear to be important for responses to immunotherapy in non–small cell lung cancer, because neoantigen-specific T